Reaction equation
Br[CH2:2][C:3]([C:5]1[C:6]([C:11]2[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=2)=[N:7][O:8][C:9]=1[CH3:10])=O.[NH2:17][C:18]1[C:23]([OH:24])=[CH:22][CH:21]=[CH:20][N:19]=1>>[CH3:10][C:9]1[O:8][N:7]=[C:6]([C:11]2[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=2)[C:5]=1[C:3]1[N:17]=[C:18]2[C:23]([OH:24])=[CH:22][CH:21]=[CH:20][N:19]2[CH:2]=1Participants
3
Procedure
As described for Example 2, 4-(bromoacetyl)-5-methyl-3-phenylisoxazole (commercially available) (140 mg, 0.5 mmol) was converted, using 2-amino-3-hydroxypyridine instead of 2-amino-3-methylpyridine, to the title compound (6 mg, 4%) which was obtained as a yellow foam. MS: m/e=292.1 [M+H]+.
Sources & evidence
- ORD record
- ord-692fd11c6c804d22b114d0afcc345613
- Source dataset
- uspto-grants-2009_09
- Patent number
- US07585874B2
Linked notes
Loading…